The HAVEN study —hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan

DiscussionThis trial aims to explore Hydroxychloroquine as a treatment for patients with AAV. If effective, the need for immunosuppressive treatments such as prednisolone could be reduced. Hydroxychloroquine is safer, cheaper and has fewer adverse effects than conventional immunosuppressive treatments. This could improve patient outcomes while saving money for the NHS.Trial registrationISRCTN: ISRCTN79334891. Registered 07 June 2021.EudraCT: 2018-001268-40. Registered 13 September 2019.Clinicaltrials.gov: NCT04316494. Registered 20 March 2020.
Source: Trials - Category: Research Source Type: clinical trials